论文部分内容阅读
目的研究次级淋巴组织趋化因子(SLC)基因转染对小鼠恶性黑色素瘤细胞生物学特性的影响。方法采用脂质体法将小鼠SLC基因转染至小鼠恶性黑色素瘤细胞中,并通过G418筛选出转基因细胞克隆。体外检测SLC基因转染恶性黑色素瘤细胞的增殖,并通过趋化小室法检测细胞培养基上清液中SLC的趋化活性。检测野生型和基因转染的恶性黑色素瘤细胞在体内的致瘤性,并病理检测肿瘤组织中免疫细胞的浸润。结果SLC基因转染的恶性黑色素瘤细胞和野生型恶性黑色素瘤细胞在体外的增殖没有明显差别。分泌于细胞培养基上清液中的SLC表现出了趋化活性。SLC基因转染并没有降低细胞的致瘤性,但是移植瘤的生长明显慢于野生型恶性黑色素瘤细胞移植瘤的生长,并且病理证实SLC基因转染的肿瘤细胞移植瘤内呈现明显的淋巴细胞浸润。结论SLC基因转染在小鼠黑色素瘤能诱导抗肿瘤免疫,有可能被应用于恶性肿瘤的免疫治疗。
Objective To study the effect of secondary lymphoid chemokine (SLC) gene transfection on the biological characteristics of mouse malignant melanoma cells. Methods Mouse SLC gene was transfected into mouse malignant melanoma cells by liposome method, and the transgenic cell clones were screened by G418. The proliferation of malignant melanoma cells transfected with SLC gene was detected in vitro, and the chemotactic activity of SLC in cell culture supernatant was detected by chemotactic chamber method. The tumorigenicity of wild-type and gene-transfected malignant melanoma cells in vivo was examined, and the infiltration of immune cells in the tumor tissue was examined pathologically. Results SLC gene transfected malignant melanoma cells and wild-type malignant melanoma cells in vitro proliferation was no significant difference. SLC secreted in cell culture supernatants showed chemotactic activity. SLC gene transfection did not reduce the tumorigenicity of the cells, but the growth of the transplanted tumor was obviously slower than that of the wild-type malignant melanoma cell xenograft, and the pathology confirmed that the transplanted tumor of the SLC gene showed obvious lymphocytes infiltration. Conclusion SLC gene transfection can induce anti-tumor immunity in mouse melanoma and may be used in the immunotherapy of malignant tumors.